Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2006-01-17
2006-01-17
Qazi, Sabiha N. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000, C514S170000
Reexamination Certificate
active
06987101
ABSTRACT:
A method for treating premenstrual dysphoric disorder comprises administering a therapeutically effective amount of a gestagen. Optionally, a natural or synthetic estrogen is also administered. In one embodiment, the gestagen and optional estrogen are administered during the luteal phase of the female menstrual cycle, preferably from day 10 to day 28.
REFERENCES:
patent: 5583129 (1996-12-01), Spona et al.
patent: 43 13 926 (1994-11-01), None
patent: 43 44 462 (1995-06-01), None
patent: 0 640 343 (1995-03-01), None
patent: 9404157 (1994-03-01), None
patent: WO 98/27929 (1998-07-01), None
Studd et al. (DN 137:273292, CAPLUS, abstract of Advances in Gynecological Endocrinology, Proceedings of the Plenary Sessions of the World Congress of Gynecological Endocrinology, 8th, Florence, Italy, Dec. 6-9, 200 (2002), Meeting Date 2000, 83-89.
Editors: Genazzani et al.; Parthenon Publishing Group; New York: N. Y.
Whilbaeck et al. AN 2004:341472 CAPLUS, abstract of Psychoneuroendocrinology (2004), 29(6), 757-766.
Freeman, E.W, AN 2003:293197, abstract of European J. of Contraceptive & Reproductive Health Care (2002), 7(Suppl. 3), 27 34.
Toriizuka et al., AN 2000:16283, CAPLUS, abstract of Nippon Yakurigaku Zasshi (2000), 115(1), 21-28.
Abstract of RAPKIN, Psychoneuroendocrinology Aug. 2003, 28 Suppl 3: 39-53.
El-Sherbini, Abbas (CA 82:68681, abstract of Ain Shams Med, J. (1974), 25(4), 579-85), 1974.
Boekler, H. (CA 78:24468, abstract of Sportarzt sportmad. (1972), 22(9), 233-4, 236-7, 1972.
Neuman, Friedmund (CA 118:161077, abstract of Pharm. Ztg. (1992), 137(34), 9-15), 1992.
Guenther et al. (CA 113:218253, abstract of WO 9004397), 1974.
Vellacott et al., “A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome,” Current Medical Research and Opinion, vol. 10, No. 7, 1987, pp 450-456.
E. Freeman et al.,Evaluation of a Unique Oral Contraceptive in the Treatment of Premenstrual Dysphoric Disorder, Journal of Women's Heath & Gender-Based Medicine, vol. 10, No. 6, 2001, pp. 561-569.
E. Freeman et al.,A Double-blind Trial of Oral Progesterone, Alprazolam, and Placebo in Treatment of Severe Premenstrual Syndrome, JAMA, vol. 274, No. 1, Jul. 5, 1995, pp. 51-57.
P.M. 'Brien et al.,Treatment of Premenstrual Syndrome by Spironolactone, British Journal of Obstetrics and Gynaecology, vol. 86, Feb. 1979, pp. 142-147.
D. Hellberg et al.,Premenstrual tension: a placebo-controlled efficacy study with spironolactone and medroxyprogesterone acetate, Int. J. Gynecol. Obstet, 1991; 34: pp. 243-248.
M. Wang et al.,Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study, Acta Obstet Gynecol Scand. 1995: 74:pp. 803-808.
R.B. Bumet et al.,Premenstrual Syndrome and Spironolactone, Aust NZ J. Obstet Gynaecol 1991; 31: 4: 366.
K. Aslasksen et al.,Spironolactone in the Treatment of Premenstrual Tension: A Double-Blind Study of Spironolactone Versus Bendroflumethiazide and Placebo, Current Therapeutic Research, vol. 49, No. 1, Jan. 1991, pp. 120-130.
El-Sherbini, Abbas (CA 82:68681, abstract of Aln Shams Med, J. (1974), 25(4), 579-85), 1974.
Boekler, H. (CA 78:24468, abstract of Sportarzi sportmad. (1972), 22(9), 233-4, 236-7, 1972.
Neuman, Friedmund (CA 118:161077, abstract of Pharm. Ztg. (1992), 137(34), 9-15), 1992.
Guenther et al. (CA 113:218253, abstract of WO 9004397), 1974.
L.L. Altshuler et al.: “Pharmacolgical management of premenstrual disorder.” Harvard Rev. Psychiat., BD 2 nR. 5, 1995, pp. 233-245.
Christine P. West, “Inhibition of ovulation with oral progestins-effectiveness in premenstrual syndrome,” European Journal of Obstetrics & Gynecology and Reproductive Biology. 34 (1990), pp. 119-128.
C. Kirkham, MD., et al., “A Randomized, Double-Blind, Placebo-Controlled, Cross-Over Tral to Assess the Side Effects of Medroxyprogesterone Acetate in Hormone Replacement Therapy,” Obstetrics & Gynecology, vol. 78, No. 1, Jul. 1991, pp. 93-97.
L. Dennerstein, et al., “Progesterone and premenstrual syndrome: a double blind crossover trial, ”British Medical Journal, vol. 290, Jun. 1, 1985, pp. 1617-1621.
Peter J. Schmidt, MD., et al., “Lack of Effect of Induced Menses on Symptoms in Women with Premenstrual Syndrome,” The New England Journal of Medicine, vol. 324, No. 17, Apr. 25, 1991, pp. 1174-1179.
John Bancroft et al., “The Impact of Oral Contraceptives on the Experience of Perimenstrual Mood, Clumsiness, Food Craving and Other Symptoms,” Journal of Psychosomatic Research, vol. 37, No. 2, 1993, pp. 195-202.
Cynthia A. Graham, et al., “A Prospective Treatment Study of Premenstrual Symptoms Using a Triphasic Oral Contraceptive,” Journal of Psychosomatic Research, vol. 36, No. 3, 1992, pp. 257-268.
Lennart Nilsson et al., “Clinical Studies on Oral Contraceptives-a Randomized, Doubleblind, Crossover Study of 4 Different Preparations (Anovlar® mite, Lyndiol® mite, Ovulen®, and Volidan®),” Acta Obstetrichet Gynecologica Scandinavica, vol. XLVI, Supplement 8, pp. 2-31, yr. 1967.
Johan Cullberg, “Mood Changes and Menstrual Symptoms with Different Gestagen/Estrogen Combinations,” Acta Psychiatrica Scandinavica, Supplementum 236, 1972, pp. 9-86.
Sam Silbergeld, Ph.D., MD., et al., “The Menstrual Cycle: A Double-Blind Study of Symptoms, Mood and Behavior, and Biochemical Variables Using Enovid and Placebo,” Psychosomatic Medicine, vol. 33, No. 5 (Sep.-Oct. 1971), pp. 411-428.
Francis J. Kane, “Iatrogenic Depression in Women,” Phenomenology and Treatment of Depression, Copyright 1977, pp. 69-81.
Mabray et al., “Treatment of Common Gynecologic-Endocrinologic Symptoms by Allergy Management Procedures,” Obstetrics & Gynecology, vol. 59, No. 5, May 1982, pp. 560-564.
B.P. Appleby, “A Study of Premenstrual Tension in General Practice,” British Medical Journal, Feb. 6, 1960, pp. 391-393.
B. Andersch et al., “Progesterone Treatment of Premenstrual Tension-A Double Blind Study,” Journal of Psychosomatic Research, vol. 29, No. 5, 1985, pp. 489-493.
Michael A. Richter, M.D., et al., “Progesterone Treatment of Premenstrual Syndrome,” Current Therapeutic Research, vol. 36, No. 5, Nov. 1984, pp. 840-850.
Gwyneth A Sampson, “Premenstrual Syndrome: A Double-Blind Controlled Trial of Progesterone and Placebo,” Brit. J. Psychiat. (1979), 135, 209-215.
Sarah Maddocks, et al., “A double-blind placebo-controlled trial of progesterone vaginal suppositories in the treatment of premenstrual syndrome,” Am J Obstet Gynecol, Mar. 1986, pp. 573-581.
Ellen Freeman, et al., “Ineffectiveness of Progesterone Suppository Treatment for Premenstrual Syndrome,” JAMA, vol. 264, No. 3, Jul. 18, 1990, pp. 349-353.
Lorraine Dennerstein, et al., “Treatment of Premenstrual Syndrome a Double-blind Trial of Dydrogesterone,” Journal of Affective Disorders, 11 (1986), pp-199-205.
Gwyneth A. Sampson, et al., “Premenstrual Syndrome A Double-blind Cross-over study of Treatment with Dydrogesterone and Placebo,” British Journal of Psychiatry, 153 (1988), pp. 232-235.
Pekka Ylostalo, et al., “Bromocriptine and Norethisterone in the Treatment of Premenstrual Syndrome,” Obstetrics & Gynecology, vol. 58, No. 3, Mar., 1982, pp. 292-298.
Malinee Sangthawan et al., A comparative study of monophasic oral contraceptives containing either drospirenone 3 mg or levonorgestrel 150 μg on premenstrual symptoms, Science Direct, Jul. 19, 2004.
Milen White Zelano & Branigan, P.C.
Qazi Sabiha N.
Schering Aktiengesellschaft
LandOfFree
Therapeutic gestagens for the treatment of premenstrual... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic gestagens for the treatment of premenstrual..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic gestagens for the treatment of premenstrual... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3576077